Therapeutic targeting of NLRP3 from day 1 with the potent NLRP3 inhibitor MCC950 also confirmed the requirement of inflammation to combat early disease, as mice were rendered more susceptible to HKx31 (H3N2) and PR8 infection by MCC950 treatment. This evidence concerns the gene NLRP3 and infection.